Patents by Inventor Walter F Boron
Walter F Boron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11873266Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g.Type: GrantFiled: July 26, 2021Date of Patent: January 16, 2024Assignee: AEROMICS, INC.Inventors: Marc F. Pelletier, George William Farr, Paul Robert McGuirk, Christopher H Hall, Walter F. Boron
-
Publication number: 20220081391Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g.Type: ApplicationFiled: July 26, 2021Publication date: March 17, 2022Inventors: Marc F. Pelletier, George William Farr, Paul Robert McGuirk, Christopher H. Hall, Walter F. Boron
-
Patent number: 11084778Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g.Type: GrantFiled: May 17, 2018Date of Patent: August 10, 2021Assignee: AEROMICS, INC.Inventors: Marc F. Pelletier, George William Farr, Paul Robert McGuirk, Christopher H. Hall, Walter F. Boron
-
Patent number: 10246733Abstract: A method and assay for using carbonic anhydrase (CA), particularly CA-I or CA-II, as a biomarker of hemolysis. The method and assay detect hemolysis by determining a percentage erythrocyte hemolysis in a specimen or sample of blood based upon quantification of carbonic anhydrase present in the extracellular portion of the blood. The method and test serve to optimize therapeutic efficacy for treatments of hemolysis.Type: GrantFiled: June 6, 2016Date of Patent: April 2, 2019Assignee: CASE WESTERN UNIVERSITYInventors: Ryan R. Geyer, Pan Zhao, Mark D. Parker, Walter F. Boron
-
Publication number: 20180334424Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g.Type: ApplicationFiled: May 17, 2018Publication date: November 22, 2018Inventors: Marc F. PELLETIER, George William FARR, Paul Robert MCGUIRK, Christopher H. HALL, Walter F. BORON
-
Patent number: 9994514Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g.Type: GrantFiled: May 8, 2013Date of Patent: June 12, 2018Assignee: AEROMICS, INC.Inventors: Marc F. Pelletier, George William Farr, Paul Robert McGuirk, Christopher H. Hall, Walter F. Boron
-
Patent number: 9573885Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g.Type: GrantFiled: June 27, 2015Date of Patent: February 21, 2017Assignee: AEROMICS, INC.Inventors: Marc F. Pelletier, George William Farr, Paul Robert McGuirk, Christopher H. Hall, Walter F. Boron
-
Publication number: 20160355867Abstract: A method and assay for using carbonic anhydrase (CA), particularly CA-I or CA-II, as a biomarker of hemolysis. The method and assay detect hemolysis by determining a percentage erythrocyte hemolysis in a specimen or sample of blood based upon quantification of carbonic anhydrase present in the extracellular portion of the blood. The method and test serve to optimize therapeutic efficacy for treatments of hemolysis.Type: ApplicationFiled: June 6, 2016Publication date: December 8, 2016Inventors: Ryan R. Geyer, Pan Zhao, Mark D. Parker, Walter F. Boron
-
Publication number: 20150342967Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g.Type: ApplicationFiled: June 27, 2015Publication date: December 3, 2015Inventors: Marc F. PELLETIER, George William FARR, Paul Robert MCGUIRK, Christopher H. HALL, Walter F. BORON
-
Publication number: 20150133405Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g.Type: ApplicationFiled: May 8, 2013Publication date: May 14, 2015Inventors: Marc F. Pelletier, George William Farr, Paul Robert Mcguirk, Christopher H. Hall, Walter F. Boron
-
Patent number: 6200776Abstract: The hNBC3 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing hNBC3 polypeptides and polynucleotides in therapy, and diagnostic assays for such.Type: GrantFiled: July 15, 1998Date of Patent: March 13, 2001Assignees: Yale University School of Medicine, SmithKline Beecham Corporation P.L.C., SmithKline Beecham Laboratories PharmaceutiquesInventors: Walter F Boron, Antoine Michel Alain Bril, Nassirah Khandoudi, Xavier Martin, Steven Charles Jupe, Christopher John Rawlings, Trudy Rachel Doe
-
Patent number: 6096517Abstract: HNBC1A polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HNBC1A polypeptides and polynucleotides in the design of protocols for the treatment of ischemia heart disease, arrhythmia, congestive heart disease, stroke and renal failure, among others, and diagnostic assays for such conditions.Type: GrantFiled: August 19, 1998Date of Patent: August 1, 2000Assignees: SmithKline Beecham Laboratories, Pharmaceutiques and Yale University School of MedicineInventors: Antoine Michel Alain Bril, Nassirah Khandoudi, Xavier Martin, Walter F Boron